Skip to main content
Download PDF

Cost minimization analysis of a hexavalent vaccine in Argentina

BMC Health Services Research volume 23, Article number: 1067 (2023) Cite this article

Abstract

Background

Argentina currently uses a pentavalent vaccine containing diphtheria, tetanus, pertussis (whole cell), Haemophilus influenza type b and hepatitis B antigens, administered concomitantly with the inactivated polio vaccine (IPV) (DTwP-Hib-HB plus IPV) in its childhood vaccination schedule. However, hexavalent vaccines containing acellular pertussis antigens (DTaP-Hib-HB-IPV) and providing protection against the same diseases are also licensed, but are only available with a private prescription or for high-risk pre-term infants in the public health program. We analyzed the cost of switching from the current schedule to the alternative schedule with the hexavalent vaccine in Argentina, assuming similar levels of effectiveness.

Methods

The study population was infants ≤ 1 year of age born in Argentina from 2015 to 2019. The analysis considered adverse events, programmatic, logistic, and vaccine costs of both schemes from the societal perspective. The societal costs were disaggregated to summarize costs incurred in the public sector and with vaccination pre-term infants in the public sector. Costs were expressed in 2021 US Dollars (US$).

Results

Although the cost of vaccines with the alternative scheme would be US$39.8 million (M) more than with the current scheme, these additional costs are in large part offset by fewer adverse event-associated costs and lower programmatic costs such that the overall cost of the alternative scheme would only be an additional US$3.6 M from the societal perspective. The additional cost associated with switching to the alternative scheme in the public sector and with the vaccination of pre-term infants in the public sector would be US$2.1 M and US$84,023, respectively.

Conclusions

The switch to an alternative scheme with the hexavalent vaccine in Argentina would result in marginally higher vaccine costs, which are mostly offset by the lower costs associated with improved logistics, fewer separate vaccines, and a reduction in adverse events.

Peer Review reports

Background

Immunization programs have been fundamental in reducing morbidity and mortality associated with many communicable diseases worldwide. For example, the use of polio vaccines since their introduction in the 1950’s has brought the near global eradication of the disease [1]. Moreover, increased access to immunization, especially in developing countries, as well as the introduction of new vaccines overtime, has helped lower the mortality rate in those under-5 years old from 17 million in 1970 to 5 million in 2020 [2, 3]. Combination vaccines have played a significant role in improving immunization coverage by allowing individuals to be vaccinated against multiple communicable diseases simultaneously, whilst simplifying programmatic and logistic requirements [4,5,6].

The Argentinean Ministry of Health created the Immunization National Commission as a scientific advisory group in 2000 to prioritize vaccinations [7]. The intention was to inform and strengthen the actions of the National Immunization Program in making evidence-based decisions regarding vaccines and immunizations when formulating recommendations in their goal to control and, whenever possible, eliminate/eradicate vaccine-preventable diseases. In 2009, a pentavalent vaccine containing diphtheria, tetanus, pertussis (whole-cell), Haemophilus influenza type b and hepatitis B (DTwP-Hib-HB) antigens was introduced in Argentina [8]. Currently, children receive the pentavalent vaccine at age 2, 4 and 6 months with a booster at age 15–18 months [9]. The inactivated polio vaccine (IPV) is also administered concomitantly with the pentavalent vaccine at 2, 4 and 6 months, with an IPV booster at 5 years [10]. However, there are also two hexavalent vaccines (containing acellular pertussis antigens) protecting against the six mentioned diseases currently licensed in Argentina: Hexaxim® (Sanofi) and Infanrix-Hexa® (GSK). Both hexavalent vaccines are only available with either a private prescription, or through the Pan American Health Organization (PAHO) for high-risk, pre-term infants in the public health program.

Despite the well-established Argentinean childhood vaccination program, coverage with the third dose of DTwP-Hib-HB in the country according to WHO/UNICEF data decreased from 83% prior to the COVID-19 pandemic to 76% (or to 81% according to official/administrative reported coverage) in 2021, with reductions in coverage with most other vaccines also observed, and with similar trends noted in other Latin American countries [11]. Globally, an estimated 25 million children were unvaccinated or under-vaccinated in 2021 [12]. Many factors are thought to have contributed to the decline in non-SARS-CoV-2 vaccinations globally, including increased vaccine misinformation, an increased number of children living in troubled settings, and COVID-19 related issues including service and supply chain disruptions, resource diversion and containment measures that limited access and availability of vaccination services [12].

Advancements in healthcare innovations increasingly necessitates that health outcome evaluations are accompanied by economic assessments to help inform decision-making about their financing. Switching to the hexavalent vaccine would be expected to simplify logistics and associated delivery infrastructure, reduce the number of injections and side effects, as well as minimize administration error which may result in better acceptability, convenience and compliance, and ultimately improved vaccination coverage [13]. Previous studies assessing the potential economic impact of introducing the hexavalent vaccine in the national childhood vaccination programs of Peru, Colombia, and Chile suggest that it would lead to additional acquisition costs, which are partial mitigated by improved logistics, and reduced incidence of adverse events [14,15,16]. Here, we assessed the differences in cost from switching from the current childhood primary and booster vaccination schedule with the pentavalent vaccine plus IPV (DTwP-Hib-HB plus IPV) to an alternative series with the hexavalent vaccine (DTaP-Hib-HB-IPV) in Argentina, assuming similar levels of effectiveness across the six biologicals of the vaccine.

Objectives

The objective of this study was to estimate the cost difference between the current childhood vaccination scheme in Argentina consisting of a pentavalent vaccine plus a polio vaccine (DTwP-Hib-HB plus IPV) (see below), compared to an alternative scheme with the hexavalent vaccine (DTaP-Hib-HB-IPV) from the societal perspective. The societal perspective considers all costs relevant to society incurred such as costs related to healthcare (out/in-patient services in the public, social security, and private sectors), interventions, logistics, as well as costs associated with lost resources (e.g. absenteeism), patient-related travel, premature death, and informal care. In addition, we disaggregated the societal costs to summarize those incurred in the public sector and with the vaccination of pre-term infants in the public sector.

Methods

Population

The study population for both schemes was composed of infants up to 1 year of age born in Argentina, taking the average annual cohort of newborns from 2015 to 2019 reported by the Argentinean Ministry of Health and publicly available without restrictions [17,18,19,20,21]. The five-year annual average was 44.0 million people and 702,704 births. Of the births, three strata were defined: full term births (≥ 37 weeks’ gestation); pre-term births defined as before 37 weeks’ gestation; and high-risk pre-term births defined as before 37 weeks’ gestation and birth weight < 1,500 g. During the time period considered there were an average 641,510 and 61,194 births at ≥ 37 and < 37 weeks’ gestation, respectively, and an average 53,238 and 7,956 infants born pre-term with a birth weight ≥ 1500 g and < 1500 g, respectively [17,18,19,20,21].

Vaccination schemes

For the current analysis, we focused on the National Immunization Program primary series and first booster for infants older than 12 months. In the current vaccination scheme, full-term and pre-term infants receive 4 doses of pentavalent vaccine (2, 4, 6 and 15 months of age), and 4 doses of IPV (2, 4 and 6 months and 5 years of age) [9]. We assumed that 50% of high-risk preterm infants receive 3 doses of the hexavalent vaccine (2, 4, and 6 months), 1 dose of pentavalent vaccine (15 months), and 1 dose of IPV (school entry), with the other 50% receiving 4 doses of pentavalent vaccine plus IPV (i.e. the same schedule as the other infants). The private insurance sector already vaccinates all eligible infants with the hexavalent vaccine for all primary series and first booster (2, 4, 6 and 15 months of age) regardless of whether they were born full-term or pre-term, including those considered high-risk (consistent with the alternative vaccination scheme). In the alternative vaccination scheme, the hexavalent vaccine was used for all primary series and first booster (at 2, 4, 6 and 15 months of age) for all eligible infants. Vaccination coverage was taken from 2015 to 2019 (Supplementary Table S1) [22].

The infant population was segmented according to coverage (where the vaccine was received in the Argentinean three-tier health system [23]: public, social security and private insurance sectors (Table 1)). The social security sector includes provincial, national union & other health maintenance organizations, and PAMI for elderly & retirees (the latter not included in the current analysis). To obtain a weighting for healthcare costs, the percentage of infants in the different sub-systems was considered to be: 37% public sector, 57% social security sector, 6% private insurance sector [24]. In our analysis, the latter two sectors (social security and private insurance) are combined and referred to as the private insurance/pre-paid sector henceforth. The number of doses distributed by the Ministry of Health corresponds to the total infant population eligible for vaccination (all newborns registered for one year). The total doses distributed by the Ministry of Health was adjusted by coverage rate but did not include the number of doses distributed in the private insurance sector.

Table 1 Vaccine distribution with the two schemes across the public and private sectors
Full size table

It was assumed that the effectiveness of the current and alternative vaccination schemes was the same, and this effectiveness was maintained with periodic boosters [25,26,27,28,29,30].

Adverse events

The adverse event rate following vaccination with vaccines containing wP and aP included in the analysis were taken from Decker et al. (Supplementary Table S2) [31], and extrapolated to the vaccination cohorts assessed. However, since the Decker et al. study did not analyze the rate of adverse events following the booster, we arbitrarily assumed that this would be the same as that after the third dose of DTP. Although adverse event rates with vaccines containing wP and aP from Zhang et al., [32] and Patterson et al., [33] were considered, we chose to use those by Decker et al. [31] to be conservative since the latter generally reported a smaller reduction in the adverse event rates with aP-containing compared to wP-containing vaccines (i.e. a smaller difference in adverse event reporting rates). For seizures and other neurological effects such as hypotonic-hyporesponsiveness, data were taken from ACIP [34] and Cody et al. [35]: the rate of seizure (with or without fever) and hypotonia-hyporesponsiveness episodes with wP containing vaccines was estimated to be 1 case/1,750 vaccinated (i.e. 0.57 cases /1,000 doses) and that with aP containing vaccines to be 0.12/1,000 doses [34, 35].

Parameters and associated costs

The parameters and associated costs included in our analysis are summarized in Table 2. It was assumed that some of the associated adverse events would give rise to health resource use (visits to the outpatient clinic, subsequent follow-up visits, emergency room visits and hospitalizations) and parental resources or actions (travel to clinic, work absenteeism). The cost impact derived from adverse event management was estimated by multiplying the proportion of affected infants for each adverse event (Table S2; according to Decker et al. [31]) with the rates obtained from the Delphi survey of 30 pediatricians (involved with inpatient or outpatient care) in Uruguay where they expressed their attitudes as well as those of the parents related to management of each respective adverse event (i.e. percent requiring visits to the outpatient clinic, the emergency room and hospitalization, follow-up visits, use of medication, parental resources/actions) according to gestational age and vaccine dose administered (Tables S3–S6). These estimates, as provided by the pediatricians, were dependent on whether the infant child was eutrophic or preterm with < 37 weeks’ gestation. For length of stay if hospitalized, a conservative approach of 1 day of hospitalization was estimated in all cases. Health system unit costs (differentiated for public, social security and private sectors) related to resource utilization due to adverse events associated with outpatient clinic visits, subsequent follow-up visits, emergency room visits, and hospitalizations were obtained from an acquired unit costs and health events IQVIA database (Table 2). In each case, parental costs related to travel to clinic and absenteeism were considered, as well as for medication usually recommended at home or in an outpatient clinic (analgesics/antipyretics [ibuprofen], and antiemetics [metochlopramide]). For costs associated with parental work absenteeism (Table 2), it was assumed that a family member lost half a working day in the outpatient clinic and emergency room, and one and half days for hospitalization, considering an employment rate of 41.5% [36]. Programmatic costs considered included labor, the supply chain, service delivery and capital costs from Portnoy et al. [37].

Table 2 Parameters and associated unit costs included in the analysis
Full size table

All costs were in 2021 prices. Vaccines and programmatic costs were listed in US dollars (US$); all other costs are listed in Argentinean pesos ($ Ars) and converted to US$ according to the exchange rate set (Arg Pesos 101.75 = US$1) by Banco Nación (average purchase-sale) on October 26th, 2021 [38] (Table 2).

A sensitivity analysis was carried out based on two vaccine coverage rate extremes: one where vaccination coverage was impacted by the COVID-19 pandemic (minimum coverage as occurred in 2020 due to the pandemic [average DTP1–3 coverage, 77% and for the fourth dose, 66%]) [39]; and the other where the recommended target coverage (95%) for each dose was assumed.

Results

Base scenario cost analysis

The costs of the current and alternative vaccination schemes from the societal perspective are summarized in Table 3. Although the cost of vaccines with the alternative scheme would be US$39.8 million (M) more than with the current scheme, these additional costs are in large part offset by fewer adverse event-associated costs (US$ − 28.8 M) and lower programmatic costs (US$ − 7.4 M) such that the overall cost of the alternative scheme would only be an additional US$3.6 M from the societal perspective (Table 3/Fig. 1).

Table 3 Summary of the costs for the current and alternative schemes from the societal perspective
Full size table
Fig. 1
figure 1

Summary of the costs of the current and alternative schemes (a), and the proportion of additional vaccine costs associated with the alternative scheme offset by fewer AE-associated costs and lower programmatic costs (b)

Current scheme (pentavalent; DTwP-Hib-HB plus IPV) and alternative (hexavalent; DTaP-Hib-HB-IPV)

Full size image

The comparative costs of the two vaccination schemes incurred through those in the public sector are summarized in Table 4. Similarly, although the cost of vaccines with the alternative scheme would be US$ 39.8 M more than with the current scheme, these additional costs are in large part offset by fewer adverse event-associated costs (US$ − 30.2 M) and lower programmatic costs (US$ − 7.4 M) such that the overall cost of the alternative scheme would only be an additional US$ 2.1 M (Table 4; Fig. 1) in the public sector.

Table 4 Summary of costs of the current and alternative schemes in the public sector
Full size table

The comparative costs of the two vaccination schemes incurred through those in the public sector with pre-term infants (< 37 weeks’ gestation) are summarized in Table 5. Although the cost of vaccines with the alternative scheme would be US$2.7 M more than with the current scheme, these additional costs are in large part offset by fewer adverse event-associated costs (US$ − 2.6 M) and lower programmatic costs (US$ − 0.6 M) such that the overall cost of the alternative scheme would only be an additional US$84,023 (Table 5; Fig. 1) in the public sector.

Table 5 Summary of the costs and current and alternative schemes for preterm infants (< 37 weeks’ gestation) in the public sector
Full size table

Alternative scenario cost analysis

Alternative scenarios were considered to reflect two (lower and upper) plausible extremes in vaccination coverage; low coverage affected by the COVID-19 pandemic and the recommended target coverage (95%) for each dose were assumed (Table 6). In the two scenarios, the cost of vaccines with the alternative scheme ranged from US$33.1 M to US$42.5 M more than the current scheme, and these additional costs would also in large part be offset by fewer adverse event-associated costs and lower programmatic costs such that the overall cost of the alternative scheme would only be an additional US$2.5 to US$3.9 M from the societal perspective, with similar outcomes observed in the public sector.

Table 6 Alternate scenario analysis
Full size table

Discussion

In this study, we considered three infant populations in Argentina from the societal perspective: all infants up to 1 year of age (inclusive of the public, social security, and private sectors); and two sub-cohorts who currently receive vaccines in the public sector (distributed by the Ministry of Health); and specifically, preterm infants < 37 weeks’ gestation (including high-risk infants) in the public sector. We compared, across these infant populations, the costs associated with the current pertussis vaccination scheme with the pentavalent vaccine plus IPV (assuming that half of the high-risk infants received the pentavalent-based scheme and the other half the hexavalent scheme) with that of a hexavalent scheme covering the same diseases. We demonstrated, assuming both vaccination schemes had similar effectiveness, that switching from the current pentavalent vaccine plus IPV to the alternative scheme with the hexavalent vaccine, would result in higher vaccine costs in all populations assessed. The higher vaccine costs associated with the hexavalent vaccine scheme are mostly offset by reduced costs for adverse events associated with aP compared with wP in the current pentavalent vaccine, as well as improved logistics and programmatic costs associated with the reduction of vaccinations in the childhood series.

Previous studies found that a switch from the pentavalent vaccine plus IPV/oral polio vaccine to the hexavalent vaccine from the Chilean and Argentinean societal perspectives would result in incremental costs of US$6.45 M and US$19.7 M, respectively [14, 40], which are much higher than in our current study. The study undertaken in Chile (and the previous Argentinean study) did not have programmatic costs from Portnoy et al. 2020 [37] available at the time of their analyses, but which we included. In addition, we also included preterm infants. Of note, a Delphi survey of pediatric experts from Uruguay was also available which assessed attitudes towards the management of each adverse event, including prescription drug and diagnostic test requirements, and rates of hospitalization following each dose of the vaccines (Unpublished data [in review]). The Delphi survey enabled us to improve the assessment of the ‘health system’s behavior’ in terms of medical care and use of resources when adverse events occur. These adjustments/refinements, to incorporate more up to date information may, in part, explain the larger differences observed in previous analyses compared with our study.

We did not take into consideration the risk of non-completion of the vaccination series due to parental apprehension, which is significantly higher in those who receive vaccines containing wP than those with aP [33]. Lower vaccine coverage could result in higher disease rates, especially for those diseases that need high vaccine coverage for prevention such as pertussis and Haemophilus influenza type B. The additional cases as a result of lower vaccine coverage and the associated costs were not considered. Additionally, the costs associated with delayed vaccinations, such as additional clinic visits, were not considered. Programmatic errors were also not considered in the current scheme and are more likely to occur when multiple vaccines are required [41, 42]. The current Argentinean vaccination schedule includes three vaccinations on the same day at the 2 and 4 month visits (pentavalent, IPV and pneumococcal conjugate 13 serotypes vaccine). The simultaneous administration of several vaccines can lead to physicians omitting one vaccine due to lack of the product, family reluctance and child discomfort; missed vaccinations due to these reasons were not included in the analysis [43, 44]. Additionally, parental absenteeism and family transfer to the healthcare center were considered for only one parent; travel with additional family members could result in added costs. Costs associated with informal workers, who do not register income or contributions to social security, were also not considered. As such, our analysis may have underestimated the benefits of switching to DTaP-Hib-HB-IPV.

We assumed the effectiveness of both wP and aP vaccines was the same. Previous studies suggest that waning immunity in children who received aP vaccines occurs more rapidly than those who received wP vaccines [45, 46]. However, it is not apparent how waning immunity affects pertussis incidence rates, particularly in children < 5 years of age. In addition, countries where only wP vaccines have been used have similar numbers of pertussis cases as countries using aP vaccines [29]. Additionally, it has been demonstrated that replacement of wP combination vaccines with aP combination vaccines enhances immunity until 6 years of age, when children receive preschool boosters [46]. As such, similar effectiveness was a reasonable assumption to prevent bias in the economic estimate.

The risk of minor adverse events such as fever, irritability, uncontrollable crying, vomiting, pain, hardening, redness and edema after vaccination are significantly lower in those who receive aP vaccines compared to wP vaccines [31,32,33]. Similarly, serious adverse events such as seizures, hyporesponse-hypotonia syndrome and apnea are less frequently reported with aP vaccines than with wP vaccines [31,32,33]. Although the incidence of serious adverse events is rare, they are a cause for parental concern and can contribute to vaccine hesitancy and loss of public trust in vaccines. As such, the more favorable safety profile of aP containing vaccines over those with wP would help alleviate parental concerns and reduce vaccine hesitancy [31,32,33].

Our base scenario assessed the 5 years before the COVID-19 pandemic (2015–2019). Similar marginally higher costs were estimated with the hexavalent vaccine scheme in sensitivity scenarios assessed, where vaccine coverage was assumed to be affected by the COVID-19 pandemic (low coverage) or when 95% coverage for each dose was assumed (recommended coverage).

In conclusion, a switch to the hexavalent vaccine scheme in Argentina would lead to marginal additional costs to society.

Data Availability

All data generated or analysed during this study are included in this published article.

References

  1. Bandyopadhyay AS, Macklin GR. Final frontiers of the polio eradication endgame. Curr Opin Infect Dis. 2020;33(5):404–10.

    Article  PubMed  Google Scholar 

  2. World Health Organization (WHO). State of the world’s vaccines and immunization. 3rd edition. World Health Organization 2009. Available at: https://apps.who.int/iris/handle/10665/44169 (accessed 8 November 2022).

  3. United Nations Children’s Fund (UNICEF). Under-five mortality. Available at: https://data.unicef.org/topic/child-survival/under-five-mortality/ (accessed 8 November 2022).

  4. Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care. 2003;9(1 Suppl):6–12.

    Google Scholar 

  5. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25(6):507–12.

    Article  PubMed  Google Scholar 

  6. Koslap-Petraco MB, Judelsohn RG. Societal impact of combination vaccines: experiences of physicians, nurses, and parents. J Pediatr Health Care. 2008;22(5):300–9.

    Article  PubMed  Google Scholar 

  7. Stecher D, Gaiano A, Biscayart C, Gentile A, Ayala SG, López E, Bonvehí P, Yedlin P, Janusz C, Vizzotti C. National Immunization Commission: strengthening evidence-based decision making in Argentina. Vaccine. 2014;32(16):1778–80.

    Article  PubMed  Google Scholar 

  8. Pan American Health Organization (PAHO). Year of introduction fo vaccines. Available at: https://ais.paho.org/imm/IM_JRF_YearVaccineIntroduction.asp (accessed 8 November 2022).

  9. World Health Organization (WHO). Vaccination schedule for Argentina. Available at: https://immunizationdata.who.int/pages/schedule-by-country/arg.html?DISEASECODE=&TARGETPOP_GENERAL= (accessed 8 November 2022).

  10. Argentina Presidencia. Legislation and Official Notices. Available at: https://www.boletinoficial.gob.ar/detalleAviso/primera/228243/20200424 (accessed 8 November 2022).

  11. World Health Organization (WHO). Diphtheria tetanus toxoid and pertussis (DTP) vaccination coverage. 2022, Available at: https://immunizationdata.who.int/pages/coverage/dtp.html (accessed 7 June 2023).

  12. United Nations Children’s Fund (UNICEF). Immunization. Available at: https://data.unicef.org/topic/child-health/immunization/ (accessed 8 November 2022).

  13. Maman K, Zollner Y, Greco D, Duru G, Sendyona S, Remy V. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother. 2015;11(9):2132–41.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Olivera I, Grau C, Dibarboure H, Torres JP, Mieres G, Lazarov L, Alvarez FP, Yescas JGL. Valuing the cost of improving chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine. BMC Health Serv Res. 2020;20(1):295.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Romero M, Gongora DS, Caicedo ML, Benchabane D, Lopez JG. Cost-minimization and Budget Impact Analysis of a Hexavalent Vaccine (Hexaxim(R)) in the colombian expanded program on immunization. Value Health Reg Issues. 2021;26:150–9.

    Article  PubMed  Google Scholar 

  16. Seinfeld J, Rosales ML, Sobrevilla A, Lopez Yescas JG. Economic assessment of incorporating the hexavalent vaccine as part of the National Immunization Program of Peru. BMC Health Serv Res. 2022;22(1):651.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Directorate of Health Statistics and Information (DEIS). Estadisticas Vitales - Informacion Basica 2015. Available at: https://ghdx.healthdata.org/record/argentina-vital-statistics-2015 (accessed 9 March 2023).

  18. Directorate of Health Statistics and Information (DEIS). Estadisticas Vitales - Informacion Basica 2016. Avilable at: https://ghdx.healthdata.org/record/argentina-vital-statistics-2016 (accessed 9 March 2023).

  19. Directorate of Health Statistics and Information (DEIS). Estadisticas Vitales - Informacion Basica 2017. Available at: https://ghdx.healthdata.org/record/argentina-vital-statistics-2017 (accessed 9 March 2023).

  20. Directorate of Health Statistics and Information (DEIS). Estadisticas Vitales - Informacion Basica 2018. Available at: https://ghdx.healthdata.org/record/argentina-vital-statistics-2018 (accessed 9 March 2023).

  21. Directorate of Health Statistics and Information (DEIS). Estadisticas Vitales - Informacion Basica 2019. Available at: https://ghdx.healthdata.org/record/argentina-vital-statistics-2019 (accessed 9 March 2023).

  22. Pan American Health Organization (PAHO). Vaccine coverage reported in the Americas. Available at: [https://ais.paho.org/imm/IM_JRF_COVERAGE.asp (accessed 20 September 2022).

  23. ExpatFocus. Argentina Health Insurance. The complete guide! Avaiable at: https://www.expatfocus.com/argentina/health/health-insurance-argentina (accessed 20 September 2022).

  24. Desarrollo Productivo y Tecnológico (DPT) and Chamber of Medical Diagnostic Institutions (CADIME): Sector Report No. 12. ; 2019. Available at: https://fundaciondpt.com.ar/wp-content/uploads/2019/03/Informe_Sectorial_N_12_marzo-2019.pdf (accessed 8 November 2022).

  25. Oliver SE, Moore KL. Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus, Haemophilus influenzae type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants. MMWR Morb Mortal Wkly Rep. 2020;69(5):136–9.

    Article  PubMed  PubMed Central  Google Scholar 

  26. von König CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis. 2002;2(12):744–50.

    Article  Google Scholar 

  27. Forsyth KD, Tan T, von Konig CW, Heininger U, Chitkara AJ, Plotkin S. Recommendations to control pertussis prioritized relative to economies: A Global Pertussis Initiative update. Vaccine. 2018;36(48):7270–5.

    Article  PubMed  Google Scholar 

  28. Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glode MP, Ehresmann KR. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998–2001. Pediatrics. 2005;116(2):e285–294.

    Article  PubMed  Google Scholar 

  29. Gentile Á, Torres-Torreti JP, López-López P, Ulloa-Gutierrez R. Epidemiologic changes and novelties on vaccination against Bordetella pertussis in Latin America. Rev Chil Infectol. 2021;38(2):232–42.

    Article  Google Scholar 

  30. Edwards KM, Decker MD. Pertussis vaccines. In: Vaccines. 5th Edition. Edited by Plotkin SA, Orenstein WA, Offit P. Philadelphia, Pennsylvania, Chap. 21:467–517. Saunders; 2008.

  31. Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, Anderson EL, Deloria MA, Reed GF. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics. 1995;96(3 Pt 2):557–66.

    Article  CAS  PubMed  Google Scholar 

  32. Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev. 2014; 2014(9):Cd001478.

  33. Patterson J, Kagina BM, Gold M, Hussey GD, Muloiwa R. Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: a systematic review. Vaccine. 2018;36(40):6007–16.

    Article  CAS  PubMed  Google Scholar 

  34. Centers for Disease Control and Prevention (CDC). Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(Rr–7):1–25.

    Google Scholar 

  35. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics. 1981;68(5):650–60.

    Article  CAS  PubMed  Google Scholar 

  36. Instituto Nacional de Estadística y Censos República Argentina. Average monthly income. Available at: https://www.indec.gob.ar/indec/web/Nivel3-Tema-4-31 (accessed 20 September 2022).

  37. Portnoy A, Vaughan K, Clarke-Deelder E, Suharlim C, Resch SC, Brenzel L, Menzies NA. Producing standardized Country-Level immunization delivery unit cost estimates. PharmacoEconomics. 2020;38(9):995–1005.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Banco Naciόn. Exchange Rate. Available at: https://www.bna.com.ar/Personas (accessed 20 September 2022).

  39. Ministry of Health: Immunopreventable Disease Control Directorate (DICEI). Situation of National Vaccination Coverage in the context of the SARS-CoV-2 Pandemic. June 14, 2021. Available at: https://www.argentina.gob.ar/salud/inmunoprevenibles (accessed 3 October 2021).

  40. Gentile Á, Giglio ND, Castellano V, López JG, Dibarboure H. [Vaccination in children under 1 year with pertussis component in the context of the global initiative for the eradication of poliomyelitis in Argentina: economic analysis]. Rev Chil Infectol. 2021;38(2):224–31.

    Article  Google Scholar 

  41. Obando-Pacheco P, Rivero-Calle I, Gómez-Rial J, Rodríguez-Tenreiro Sánchez C, Martinón-Torres F. New perspectives for hexavalent vaccines. Vaccine. 2018;36(36):5485–94.

    Article  CAS  PubMed  Google Scholar 

  42. World Health Organization (WHO). Meeting of the Strategic Advisory Group of experts on immunization, April 2015: conclusions and recommendations. Wkly Epidemiol Rec. 2015;90(22):261–78.

    Google Scholar 

  43. Elas M, Villatoro N, Pezzoli L. Disproportionality analysis of reported drug adverse events to assess a potential safety signal for pentavalent vaccine in 2019 in El Salvador. Vaccine. 2021;39(34):4849–55.

    Article  CAS  PubMed  Google Scholar 

  44. World Health Organization (WHO): WHO Drug Information. 2014; 28: 295–378.

  45. Smits K, Pottier G, Smet J, Dirix V, Vermeulen F, De Schutter I, Carollo M, Locht C, Ausiello CM, Mascart F. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination. Vaccine. 2013;32(1):111–8.

    Article  CAS  PubMed  Google Scholar 

  46. van der Lee S, Hendrikx LH, Sanders EAM, Berbers GAM, Buisman A-M. Whole-cell or Acellular Pertussis Primary Immunizations in Infancy determines adolescent Cellular Immune Profiles. Front Immunol. 2018; 9.

  47. K@iros I. Suspension. NSAIDs (antipyretic-analgesic). IBUPIRAC 2% SUSPENSION 2 g/100ml (Pfizer). Available at: https://ar.kairosweb.com/precio/producto-ibupirac-2--suspension-17411/ (accessed 20 September 2022).

  48. K@iros. Ibuprofen Suspension. NSAID (antipyretic-analgesic) FEBRATIC Ped. 2% (Roemmers). Available at: https://ar.kairosweb.com/precio/producto-febratic-12837/ (accessed 20 September 2022).

  49. K@iros. Ibuprofen Suspension. NSAID (antipyretic-analgesic) PEDIATRIC ACTRON 2% Oral (Bayer). Available at: https://ar.kairosweb.com/precio/producto-actron-pediatrico-15292/ (accessed 20 September 2022).

  50. K@iros, Metclopramide. Antiemetic. RELIVERAN CHILDREN 2 mg/ml. Oral drops x20ml (Gador). Available at: https://ar.kairosweb.com/precio/producto-reliveran-3741/ (accessed 20 September 2022).

  51. K@iros, Metoclopramide. Antiemetic. Vannier 5 mg /ml. Oral Drops x 20ml. (Vannier). Available at: https://ar.kairosweb.com/precio/producto-metoclopramida-vannier-8404/ (accessed 20 September 2022).

  52. K@iros, Metoclopramide. Antiemetic. Gastrocalm 2 mg /ml. Oral Drops x 20ml. (Cassará). Available at: https://www.alfabeta.net/precio/gastrocalm.html (accessed 20 September 2022).

  53. IQVIA Argentina. Unit Cost and Events Database: Answering the Need for Methodological Homogeneous and Representative Costs in Argentina in a Context of Healthcare Fragmentation. ISPOR 15–18. May 2022, Washington, DC, USA.

  54. Minsterio de Transporte. AMBA public transport fares 2021. Avialable at: https://www.argentina.gob.ar/redsube/tarifas-de-transporte-publico-amba-2021.

  55. Pan American Health Organization (PAHO). Vaccine Prices Revolving Fund for 2021. Available at: https://www.paho.org/es/documentos/precios-vacunas-fondo-rotatorio-para-2021 (accessed 20 September 2022).

  56. K@iros. Cost vaccine Hexavalent private health subsector Hexaxim (Sanofi). Available at: https://ar.kairosweb.com/precio/producto-hexaxim-24482/ (accessed 20 September 2022).

  57. K@iros. Hexavalent values. Cost vaccine Hexavalent private health subsector Infanrix Hexa (GSK). Available at: https://ar.kairosweb.com/precio/producto-infanrix-hexa-13395/ (accessed 20 September 2022).

Download references

Acknowledgements

Editorial assistance with preparation of the manuscript was provided by Holly McAlister and Richard Glover, of inScience Communications, Springer Healthcare Ltd, UK, and was funded by Sanofi. The authors also wish to acknowledge and thank the Sanofi study team for the support during the conduct of this study, and Roopsha Brahma, PhD, for editorial assistance and manuscript coordination on behalf of Sanofi.

Funding

This study was funded by Sanofi.

Author information

Authors and Affiliations

  1. Centro de Investigaciones Económicas, CINVE, Salud, Montevideo, Uruguay

    Ignacio Olivera, Carlos Grau Pérez & Luis Lazarov

  2. Facultad de Medicina, Universidad del Salvador, Buenos Aires, Argentina

    Eduardo Lopez

  3. Sanofi Vaccines, Buenos Aires, Argentina

    Cristian Oddo

  4. Sanofi Vaccines, Montevideo, Uruguay

    Hugo Dibarboure

  5. Cuyo 3512, Martinez, Buenos Aires, B1640GIY, Argentina

    Cristian Oddo

Authors
  1. Ignacio Olivera
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos Grau Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luis Lazarov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eduardo Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cristian Oddo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hugo Dibarboure
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

I.O., C.G.P., L.L., E.L, C.O., and H.D. contributed to the concept or design of the study, were involved in data acquisition and/or analysis/interpretation of the data. All authors participated in the drafting and revision of this report and approved the final version for publication.

Corresponding author

Correspondence to Cristian Oddo.

Ethics declarations

Ethics approval and consent to participate

The data used for the study is publicly available and therefore ethics approval was not required.

Consent for publication

Not applicable.

Competing interests

CO and HD are employees of Sanofi and may hold shares and/or stock options in the company. IO, CGP, LL, and EL have no relevant conflict of interest to report.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Olivera, I., Pérez, C.G., Lazarov, L. et al. Cost minimization analysis of a hexavalent vaccine in Argentina. BMC Health Serv Res 23, 1067 (2023). https://doi.org/10.1186/s12913-023-10038-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12913-023-10038-0

Keywords

BMC Health Services Research

ISSN: 1472-6963

Contact us